SCHEMBL25756943

SCHEMBL25756943

CCC(=O)c1cnn2ccc(NC(=O)OC(C)(C)C)c(OC)c12

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.37
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
EPHB3 P54753 1/20 0.33
ATR Q13535 1/20 0.33
IRAK4 Q9NWZ3 5/20 0.33
PCSK9 Q8NBP7 1/20 0.33
CYP17A1 P05093 1/20 0.33
JAK2 O60674 1/20 0.32
NTRK1 P04629 1/20 0.32
CNR2 P34972 1/20 0.32
MAPT P10636 2/20 0.32
PDE2A O00408 1/20 0.32
LMNA P02545 1/20 0.32
HSD17B10 Q99714 1/20 0.32
BRD9 Q9H8M2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25757841 0.88 ATR (0.35) IDO1KDM4EALDH1A1EPHB3ATR
SCHEMBL25757107 0.88 ATR (0.42) IDO1KDM4EALDH1A1EPHB3ATR
SCHEMBL25757792 0.88 ATR (0.35) IDO1KDM4EALDH1A1EPHB3ATR
SCHEMBL18839993 0.88 MAPT (0.42) KDM4EALDH1A1MAPTLMNA
SCHEMBL30895044 0.86 PCSK9 (0.36) IDO1KDM4EALDH1A1ATRIRAK4
SCHEMBL27199383 0.85 IRAK4 (0.37) KDM4EALDH1A1EPHB3IRAK4MAPT
SCHEMBL30895038 0.83 ITGA4 (0.36) IDO1KDM4EALDH1A1ATRIRAK4
SCHEMBL30895110 0.83 DGAT1 (0.35) IDO1EPHB3ATRIRAK4PCSK9
SCHEMBL25756944 0.83 PCSK9 (0.35) IDO1KDM4EALDH1A1ATRPCSK9
SCHEMBL25757842 0.83 IDO1 (0.37) IDO1ATRPCSK9CYP17A1BRD9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
CN-118401516-A TYK2 inhibitors, compositions and methods thereof 凌科药业(杭州)有限公司 2024-07-26 CN disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 IDO1 570/4885KDM4E 404/4885ALDH1A1 4805/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 IDO1 570/4885KDM4E 404/4885ALDH1A1 4805/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 IDO1 570/4885KDM4E 404/4885ALDH1A1 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.